Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00810758 | Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691 | PHASE1 | COMPLETED | 24 | — | — | Jan 1, 2009 | Nov 1, 2009 | Dec 1, 2009 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| PF-04878691 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-04878691 3mg | DRUG | Oral solution, 3mg, twice weekly, 2 weeks |
| PF-04878691 6mg | DRUG | Oral solution, 6mg, twice weekly, 2 weeks |
| PF-04878691 9mg | DRUG | Oral solution, 9mg, twice weekly, 2 weeks |
Inclusion Criteria: * Healthy male and/or female subjects between the ages of 18-55, inclusive. * Body Mass Index (BMI) of 18-30 kg/m2; total body weight \>50kg (110lbs). Exclusion Criteria: * Pregnant or nursing females. * Females of child-bearing potential. * Evidence of history of clinically s...